Launched with fanfare at the White House, the deal with Pfizer to provide discounts to Medicaid through the Most Favored Nation pricing effort may not have a big impact on lowering drug prices, and any impact will not likely be seen in the short term, industry leaders say. President Donald Trump, along with Pfizer chairman and CEO Albert Bourla, announced the deal at a press conference on Tuesday. The deal requires Pfizer to offer medications at a discount and invest in production in the United States.

Pfizer is only offering six products that can be accessed through TrumpRx.gov when the website goes live sometime next year (see Table below) , including some that are very high priced. Even with a discount, these therapies would be out of reach for cash-paying patients.

For example, Xel

See Full Page